Lu-AAZTA-NI-PSMA-093

Lu-AAZTA-NI-PSMA-093 enhances tumor uptake and retention by combining a hypoxia-sensitive nitroimidazole (NI) moiety with a targeting moiety to PSMA. Lu-AAZTA-NI-PSMA-093 can be used in prostate cancer[1].

Product Specifications

UNSPSC

12352211

Target

Radionuclide-Drug Conjugates (RDCs)

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lu-aazta-ni-psma-093.html

Smiles

O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC([C@@H](NC(COC1=CC=C(C[C@H](NC(CNC(CC[C@H](NC(CCCCC2(N(CC(O3)=O)CC(O4)=O)C[N@]5(CC(O[Lu]6435OC(C7)=O)=O)CC[N@]67C2)=O)C(NCCCN8C=CN=C8[N+]([O-])=O)=O)=O)=O)C(O)=O)C=C1)=O)CC9=CC=CC=C9)=O)=O

Molecular Formula

C63H82LuN14O26

Molecular Weight

1626.37

References & Citations

[1]Luo Y, et al., 68Ga/177Lu-Labeled Bivalent Agents for Targeting Hypoxia and PSMA-Binding in Prostate Cancer. J Med Chem. 2024 Aug 8;67 (15) :13491-13506.